Literature DB >> 2460544

Defective E beta expression in three mouse H-2 haplotypes results from aberrant RNA splicing.

F M Tacchini-Cottier1, P P Jones.   

Abstract

The molecular basis for the defective expression of the mouse class II E beta genes in the H-2w17, H-2q, and H-2f haplotypes has been examined. The results of nuclear run-on transcription and S1 nuclease digestion assays demonstrate that E beta transcription is normal in these haplotypes. Northern blot analyses reveal reduced amounts of E beta RNA of both normal and aberrant size in the w17 and q haplotypes; an even more reduced level of E beta RNA of normal size was detected in the f haplotype. In the preceding study, we reported that the only defect detected in the E beta w17 gene is a single nucleotide insertion in the 5' RNA splice site of the first intervening sequence. S1 nuclease analysis of E beta w17 RNA indicates that splicing at this site is aberrant. One major cryptic RNA splice site is used, leading to reduced amounts of aberrantly processed RNA. Limited use of the mutated splice site and of a second cryptic site also is detected. In all three cases, stop codons in the resulting RNA would prevent their translation. The molecular defect in E beta q appears identical to that of E beta w17. In the f haplotype, even more reduced levels of E beta RNA of both normal and aberrant sizes are found. We thus show that in the three defective E beta alleles, two distinct defects are responsible for the absence of E beta protein synthesis; both of these defects affect RNA processing.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460544

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Evolution of class II genes: role of selection in both the maintenance of polymorphism and the retention of non-expressed alleles.

Authors:  P P Jones; A B Begovich; F M Tacchini-Cottier; T H Vu
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

2.  Sequence analysis of MHC class II Eb cDNAs from H2r and H2p haplotypes.

Authors:  B Y Wei; H Cao; S Pan; C S David
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

3.  Localization of a critical restriction site on the I-A beta chain that determines susceptibility to collagen-induced arthritis in mice.

Authors:  R Holmdahl; M Karlsson; M E Andersson; L Rask; L Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

4.  High frequency of H-2E0 alleles among wild mice.

Authors:  F Figueroa; H Tichy; G Singleton; S Franguedakis-Tsolis; J Klein
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

5.  An E alpha E beta heterodimer dramatically alters selection of functional T-cell subsets in A.CA transgenic mice.

Authors:  S Ishikawa; C Kowal; B Diamond
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

6.  Alteration of the T-cell receptor repertoire in A.CA mice expressing an Ead transgene.

Authors:  S Ishikawa; M Y Chang; B Diamond
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

7.  Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice.

Authors:  G Strauss; D A Vignali; G Schönrich; G J Hämmerling
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

8.  An altered splice site is found in the DRB4 gene that is not expressed in HLA-DR7,Dw11 individuals.

Authors:  V R Sutton; B K Kienzle; R W Knowles
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

9.  In vivo expression and function of hybrid Ia dimers (E alpha A beta) in recombinant and transgenic mice.

Authors:  G D Anderson; C S David
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

10.  Relative V beta transcript levels in thymus and peripheral lymphoid tissues from various mouse strains. Inverse correlation of I-E and Mls expression with relative abundance of several V beta transcripts in peripheral lymphoid tissues.

Authors:  C Y Okada; I L Weissman
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.